Market Synopsis: The Global Acute Intermittent Porphyria industry is projected to grow from USD 4.61 Billion in 2024 to USD 7.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.90% during the forecast period (2024 - 2032). The risk factors associated with acute intermittent porphyria, which include liver cancer (hepatocellular carcinoma), kidney failure,...